BEMA(TM) Fentanyl Phase III Data Demonstrating Efficacy And Tolerability To Be Presented At American Pain Society Annual Meeting

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and commercial partner Meda Pharmaceuticals will present, data from Phase III clinical pivotal trials for BEMA? Fentanyl, a potential treatment for breakthrough pain (BTP) in opioid tolerant patients with cancer. The presentations will be made at the 27th Annual Scientific Meeting of the American Pain Society (APS) in Tampa, Florida.

More: continued here

Filed under: Pain / Anesthetics on May 15th, 2008